Skip to content
KRYS·Nasdaq·US

Krystal Biotech

Krystal Biotech is a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. It uses a patented gene therapy technology platform based on engineered herpes simplex virus-1 to create vectors that deliver therapeutic transgenes to cells in multiple organ systems, supported by two in-house commercial scale CGMP manufacturing facilities. Its first commercial product, VYJUVEK, is approved in the United States, the European Union, and Japan for the treatment of dystrophic epidermolysis bullosa.

Source: SEC 10-K Feb 17, 2026

Thematic Position

KRYS

Relationship Groups

Competitors19

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

export controlsanctionanti-corruption
U.S. export controls and OFAC sanctions restrict international operations
SEC 10-KFeb 17, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.